Investigating Chloroethylamines as Anti-Tumor Drugs
Author Information
Author(s): L. F. Larionov
Primary Institution: Institute of Experimental Pathology and Therapy of Cancer, Academy of Medical Sciences, Moscow, U.S.S.R.
Hypothesis
Can chloroethylamines be effective anti-tumor drugs?
Conclusion
Chloroethylamines, particularly Embichin and its derivatives, show promise in treating Hodgkin's disease and leukemia with fewer side effects compared to traditional therapies.
Supporting Evidence
- Embichin was found to achieve therapeutic effects while sparing the haemopoietic system.
- Novoembichin was better tolerated by patients and caused fewer side effects.
- Lymphochin showed less effectiveness than Embichin and Novoembichin but was well tolerated.
- Dopan demonstrated strong anti-tumor action in animal models.
- Sarcolysine was effective against certain human malignant tumors.
Takeaway
Doctors are testing new medicines to help people with cancer, and some of these new medicines work better and are easier on the body than older treatments.
Methodology
The study involved experimental and clinical investigations of chloroethylamines, including Embichin and its derivatives, on cancer patients and animal models.
Limitations
The effectiveness of chloroethylamines on typical malignant tumors was limited, and some patients experienced side effects.
Participant Demographics
Patients with Hodgkin's disease and leukemia were treated, with some studies conducted on rabbits.
Want to read the original?
Access the complete publication on the publisher's website